Galderma, a pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population.

While the rates and stages of adoption differ worldwide, the use of prescription weight loss medications is set to increase globally, with $100 billion sales globally forecasted by 2030, which will have a considerable impact on aesthetics for both patients and healthcare professionals. With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation, there is a clear need for guidance on how to treat this new patient population.

First international consensus-based guidelines

Recognizing the significance and broad impact of prescription weight loss medications, Galderma commissioned the Delphi study to address the need for high-quality research in this area and help establish clinical guidelines for identifying and managing the unique needs of this patient population. This international, multidisciplinary study — incorporating patient interviews, market research, literature reviews, and insights from global experts with extensive experience in treating medication-driven weight loss patients — culminated in a global consensus on key criteria, expert perspectives, and treatment prioritization, all supported by real-world case studies. These novel consensus guidelines, submitted for publication as the first international consensus-based guidelines from global experts on how to treat this patient population, will be presented by Dr. Andreas Nikolis, during a focus session on “Rapid facial volume loss: causes and consequences” on January 31st, 2025 in the Grand Amphi.

Additionally, Galderma has surveyed more than 1,000 male and female respondents using weight loss medications, aged between 25-65 across the United States, Brazil, Europe and the Middle East. The focus is understanding the anatomical and aesthetic impact of medication-driven weight loss on the skin, to help equip healthcare professionals to guide patients effectively along their weight loss and aesthetics journey, based on their unique needs.

Medication-driven weight loss can lead to a myriad of facial changes, from dry or dull skin to sagging and a gaunt, hollowed-out appearance, as well as alterations in facial structure and balance. Nearly half (48%) of respondents report significant facial changes due to weight loss treatment. Menopausal women, in particular, experience higher levels of sagging skin, a slimmer face, and less radiant skin1. Loose or sagging skin on the face and neck is often noted after some weight loss, with facial changes typically observed 3-6 months following treatment (45%), and sometimes as early as 1-2 months (28%). These changes occur for several reasons: the loss of fat that typically stretches and cushions the skin, contributing to a youthful appearance, can lead to volume depletion and sagging. Additionally, the reduction of collagen, elastin, and other essential nutrients can affect skin quality, facial definition, and contouring.

60% of aesthetic users have undergone treatments to address these effects, while one third of aesthetic considerers would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their weight loss journey. The data further reveals that a significant barrier to pursuing aesthetic treatments is the lack of education and information, affecting both current and potential aesthetic users, regardless of their geographical location or stage in the weight loss process. Further, more than 60% of patients experiencing medicine-driven weight loss show a strong interest in a dual-expertise service that integrates medical and aesthetic professionals to support them during their journey. These findings from Galderma’s research show that a new, holistic approach to weight loss planning could better support this specific patient population and the healthcare professionals who treat them.

Specifically, 48% of respondents in the study reported that they would undergo Sculptra® treatment and 41% would undergo Restylane® treatment, to address the changes experienced on their face as a result of weight loss treatment, demonstrating the need for different aesthetic treatments that address the impact on their skin throughout their weight loss journey.

Read more at Business Wire >>